Skip to main
TNYA

Tenaya Therapeutic (TNYA) Stock Forecast & Price Target

Tenaya Therapeutic (TNYA) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tenaya Therapeutics Inc is advancing its preclinical product candidates, particularly TN-201 and TN-401, with improved projected chances of success, which have been raised to 30% and 15%, respectively. Positive trends in clinical data, including significant improvements in left ventricular mass index (LVMI) and vector copy number (VCN) associated with MyBP-C protein levels, indicate promising results that may support potential accelerated approvals for its therapies. Additionally, the encouraging safety profile observed in the initial cohorts strengthens the confidence in the company's ability to deliver effective curative therapies targeting heart disease.

Bears say

Tenaya Therapeutics's stock faces a negative outlook primarily due to the potential delays in transitioning its preclinical assets to clinical trials, which could significantly impact market sentiment and lead to downward revisions of financial estimates. Additionally, the emergence of critical safety signals, such as immune reactions during clinical evaluations, could further exacerbate concerns about the company's viability and product efficacy. Moreover, inadequate manufacturing capacity to support product development poses a severe risk to Tenaya's growth forecasts and overall financial stability.

Tenaya Therapeutic (TNYA) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tenaya Therapeutic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tenaya Therapeutic (TNYA) Forecast

Analysts have given Tenaya Therapeutic (TNYA) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Tenaya Therapeutic (TNYA) has a Strong Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tenaya Therapeutic (TNYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.